AI assistant
Anteris Technologies Global Corp. — Capital/Financing Update 2014
May 18, 2014
33869_rns_2014-05-18_87bfc286-f58c-41e0-9793-02f86cb5914b.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [208 x 64] intentionally omitted <==
ADMEDUS Ltd ABN 35 088 221 078
Share Purchase Plan
REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000
PO Box 6879 East Perth Western Australia 6892
19 May 2014
Dear Shareholders,
T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E [email protected]
On 12 May 2014 Admedus announced a Share Purchase Plan ( SPP ) open to eligible shareholders. This is your invitation to participate in the SPP and enclosed is a copy of the SPP booklet. Please read it carefully.
Details of how we propose to use the funds raised via this SPP and the recent $8 million placement are outlined in the booklet.
Your Company has made solid progress since I last wrote to you, with notable achievements this year including gaining FDA approval for CardioCel[®] and positive interim Phase I results for the lead therapeutic vaccine.
Some of the many initiatives we are now focusing on include;
-
increasing revenue from sales of CardioCel[®] in Europe and the US;
-
seeking approvals for CardioCel[® ] in other jurisdictions such as in Asia and Canada; and
-
initiation of HSV-2 therapeutic vaccine Phase II trials.
The SPP Application Forms are included in the booklet and are also available on our website at: www.admedus.com
If you require information on how to complete the Application Form please contact the Share Registry on: Within Australia 1300 850 505 International +61 3 9415 4000
We look forward to your ongoing support as we continue to build an integrated healthcare company.
Yours sincerely,
Chris Catlow Chairman
Perth • Brisbane • Melbourne • Minneapolis • Zurich